Treatment of muscle spasticity in patients with cerebral palsy using BTX-A: a pilot study.
This study was designed to verify the safety and efficacy of botulinum toxin type A (BTX-A) used as a neuromuscular block on spastic masticatory musculature of children with cerebral palsy. Six patients who had spastic-tetraplegic cerebral-palsy, aged 5 to 20 years were selected. All patients had spasticity of the jaw muscles, bruxism, lower lip trauma, limited mouth opening, and difficulties in cleaning the oral cavity. The patients were sedated under general anesthesia, while the dentist injected the masseter and temporalis muscles bilaterally with 150 and 75 units of BTX-A each. Clinical examinations were conducted at 7, 14, 30, and 90 days after the initial appointment. We found statistically significant decreases in muscle spasticity and bruxism (p = 0.002), improved inter-incisal opening (p = 0.002), improved oral hygiene (p = 0.031), and less lower lip trauma (p = 0.060) after the neuromuscular blocking.
Manzano
Felipe Scalco
FS
Dental Unit, Lar Escola São Francisco, São Paulo, Brazil.
Granero
Lucia Mercuri
LM
Masiero
Danilo
D
dos Maria
Teresa Botti Rodrigues
TB
D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002012:Bruxism / Q000628:therapy; D002547:Cerebral Palsy / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008046:Lip / Q000293:injuries; D008297:Male; D008334:Mandible / Q000503:physiopathology; D008406:Masseter Muscle / Q000503:physiopathology; D009068:Movement; D009128:Muscle Spasticity / Q000628:therapy*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009910:Oral Hygiene; D010865:Pilot Projects; D012449:Safety; D013703:Temporal Muscle / Q000503:physiopathology; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A